Douglas Fisher Net Worth

Douglas Fisher biography

Dr. Douglas Fisher is Independent Director of the company since May 2012. Dr. Fisher is currently an Executive in Residence at InterWest Partners LLC, a venture capital firm, where he has worked since March 2009. Dr. Fisher also serves as the Chief Business Officer at Sera Prognostics, Inc., where he has worked since January 2015. Prior to joining InterWest, Dr. Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity and venture capital firm, from January 2006 to March 2009. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm, from November 2003 to February 2006. Dr. Fisher currently serves on the board of Gynesonics, Inc., Indi Molecular, Inc. and QuatRx Pharmaceuticals Company and previously served on the board of Cardiac Dimensions, PMV Pharmaceuticals, Inc., and Sera Prognostics, Inc. Dr. Fisher holds an A.B. and a B.S. from Stanford University, an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania.

How old is Douglas Fisher?

Douglas Fisher is 40, he's been the Independent Director of Obalon Therapeutics Inc since 2012. There are 13 older and no younger executives at Obalon Therapeutics Inc. The oldest executive at Obalon Therapeutics Inc is Raymond Dittamore, 73, who is the Independent Director.

What's Douglas Fisher's mailing address?

Douglas's mailing address filed with the SEC is C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN, CT, 06511.

Insiders trading at Obalon Therapeutics Inc

Over the last 8 years, insiders at Obalon Therapeutics Inc have traded over $0 worth of Obalon Therapeutics Inc stock and bought 3,260,355 units worth $6,939,913 . The most active insiders traders include Parters Vii L Pblair James ..., Partners X Lp Inter West Ma... und David Moatazedi. On average, Obalon Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $432,771. The most recent stock trade was executed by William J. Plovanic on 12 November 2019, trading 65,000 units of OBLN stock currently worth $107,900.

What does Obalon Therapeutics Inc do?

Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

Obalon Therapeutics Inc executives and stock owners

Obalon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Kelly Huang Ph.D.,
  Consultant
• Andrew Rasdal,
  Chairman of the Board, President, Chief Executive Officer
• Andrew P. Rasdal,
  CEO, Pres & Director
• Sharon Stevenson,
  Independent Director
• Lesley Howe,
  Independent Director
• Douglas Fisher,
  Independent Director
• Raymond Dittamore,
  Independent Director
• William Plovanic,
  Director
• Robert MacDonald,
  Chief Retail Officer
• Donald Young,
  Vice President of Quality Assurance
• Todd Wood,
  Vice President - Global Sales
• Lisa Metzner,
  Vice President of Marketing
• Matthew Norwood,
  Vice President of Sales
• Steve Johnson,
  Vice President - Operations
• Nooshin Hussainy,
  Chief Financial Officer
• Nooshin Hussainy,
  CFO & Sec.
• Kim P. Kamdar,
  
• Erin Morisey,
  VP Strategic Partnerships
• Partners X Lp Inter West Ma...,
  
• David Moatazedi,
  
• Vii Associates Lpblair Jame...,
  
• Parters Vii L Pblair James ...,
  
• Amy Vanden Berg,
  Chief Clinical & Reg Officer
• Kelly Huang,
  Pres & Chief Executive Officer
• Robert H Jr Mondore,
  VP of Operations
• Jonah Shacknai,
  
• Partners X Lp Inter West Ma...,
  
• Daina Schmidt,
  Vice President of Marketing
• Mark Brister,
  Chief Technology Officer